Ligand Pharmaceuticals Incorporated

Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Ligand First Quarter 2023 Earnings Webcast

Portfolio

Portfolio

Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.

Learn More
Technologies

Technologies

Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.

Learn More
Licensing Opportunities

Licensing Opportunities

Ligand has multiple technologies and unpartnered programs available for out-licensing.

Learn More

Investor Relations

View Investor Relations Latest Corporate Presentation

Latest News

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Read More

Ligand Appoints Martine Zimmermann to its Board of Directors

Read More

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range